AIM: The herbal medicine St. John's Wort (SJW) causes substantial decreases in the plasma concentrations of a range of co-administered drugs. Therefore, we evaluated the extent of systemic exposure to hyperforin and hypericin, two of the main constituents of SJW, in patients on admission and during hospital stay, and compared the results with known use of SJW as documented in the drug chart and detected in additional interviews. METHODS: One hundred and fifty patients aged > or = 18 years and admitted, between August 2000 and February 2002, to an internal medicine ward of a large German university hospital were included. Hyperforin and hypericin was determined in plasma by a sensitive liquid chromotography/mass spectometry (LC/MS/MS) method. To assess undeclared use of SJW the data were compared to information obtained from drug charts and from up to three interviews that had a particular focus on intake of herbal medicines and self-medication during hospitalization. RESULTS: Hyperforin was detected in 12 patients (plasma concentration on the first day of hospitalization = 12-100 ng ml(-1) in five patients and < 3 ng ml(-1) in seven), and hypericin in five patients (0.5-4.3 ng ml(-1)). Nine patients (6%) were taking/had taken SJW without the knowledge of the medical team and the pharmacist, who conducted the additional interviews, and 11 (7.3%) were taking/had taken SJW without the knowledge of the medical team alone. Seven of these patients were treated concurrently with drugs that can interact with SJW. CONCLUSIONS: Unrecognized use of SJW is frequent and may have an important influence on the effectiveness and safety of drug therapy during hospital stay. Copyright 2004 Blackwell Publishing Ltd
AIM: The herbal medicine St. John's Wort (SJW) causes substantial decreases in the plasma concentrations of a range of co-administered drugs. Therefore, we evaluated the extent of systemic exposure to hyperforin and hypericin, two of the main constituents of SJW, in patients on admission and during hospital stay, and compared the results with known use of SJW as documented in the drug chart and detected in additional interviews. METHODS: One hundred and fifty patients aged > or = 18 years and admitted, between August 2000 and February 2002, to an internal medicine ward of a large German university hospital were included. Hyperforin and hypericin was determined in plasma by a sensitive liquid chromotography/mass spectometry (LC/MS/MS) method. To assess undeclared use of SJW the data were compared to information obtained from drug charts and from up to three interviews that had a particular focus on intake of herbal medicines and self-medication during hospitalization. RESULTS:Hyperforin was detected in 12 patients (plasma concentration on the first day of hospitalization = 12-100 ng ml(-1) in five patients and < 3 ng ml(-1) in seven), and hypericin in five patients (0.5-4.3 ng ml(-1)). Nine patients (6%) were taking/had taken SJW without the knowledge of the medical team and the pharmacist, who conducted the additional interviews, and 11 (7.3%) were taking/had taken SJW without the knowledge of the medical team alone. Seven of these patients were treated concurrently with drugs that can interact with SJW. CONCLUSIONS: Unrecognized use of SJW is frequent and may have an important influence on the effectiveness and safety of drug therapy during hospital stay. Copyright 2004 Blackwell Publishing Ltd
Authors: K Sugimoto; M Ohmori; S Tsuruoka; K Nishiki; A Kawaguchi; K Harada; M Arakawa; K Sakamoto; M Masada; I Miyamori; A Fujimura Journal: Clin Pharmacol Ther Date: 2001-12 Impact factor: 6.875
Authors: M Wurglics; K Westerhoff; A Kaunzinger; A Wilke; A Baumeister; J Dressman; M Schubert-Zsilavecz Journal: J Am Pharm Assoc (Wash) Date: 2001 Jul-Aug
Authors: J M Jacobson; L Feinman; L Liebes; N Ostrow; V Koslowski; A Tobia; B E Cabana; D Lee; J Spritzler; A M Prince Journal: Antimicrob Agents Chemother Date: 2001-02 Impact factor: 5.191
Authors: L B Moore; B Goodwin; S A Jones; G B Wisely; C J Serabjit-Singh; T M Willson; J L Collins; S A Kliewer Journal: Proc Natl Acad Sci U S A Date: 2000-06-20 Impact factor: 11.205
Authors: Florentine Carow; Karin Rieger; Ingeborg Walter-Sack; Markus R Meyer; Frank T Peters; Hans H Maurer; Walter E Haefeli Journal: Eur J Clin Pharmacol Date: 2012-02-22 Impact factor: 2.953
Authors: Andrea Huppertz; Lars Werntz; Andreas D Meid; Kathrin I Foerster; Jürgen Burhenne; David Czock; Gerd Mikus; Walter E Haefeli Journal: Br J Clin Pharmacol Date: 2018-10-11 Impact factor: 4.335